secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001558370-25-010640
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Q2 net loss widens to $15.4M; advances ATI-2138, bosakitug, ATI-052 trials
--------------------------------------------------------------------------------

- Net loss $15.4M vs $11.0M YoY; revenue $1.8M, down 36% due to prior royalty sale.
- Cash, equivalents & securities $180.9M; runway into H2 2028 without new financing.
- Phase 2a ATI-2138 met primary/key secondary endpoints; confirms tolerability in moderate-to-severe AD.
- Phase 2 trial of bosakitug (anti-TSLP mAb) in AD dosing; top line expected H2 2026.
- Roland Kolbeck appointed CSO replacing Joe Monahan (planned retirement through Q1 2026).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837025010640/0001558370-25-010640-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837025010640/acrs-20250807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010640

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer